View Single Post
Old 11-14-2016, 08:52 PM
zanpar321 zanpar321 is offline
Member
 
Join Date: Feb 2014
Posts: 365
10 yr Member
zanpar321 zanpar321 is offline
Member
 
Join Date: Feb 2014
Posts: 365
10 yr Member
Default

Quote:
Originally Posted by zanpar321 View Post
The Prothena drug seems to be quite promising as it reduces the alpha synuclein protein that the prevailing science seems to be believed to be the protein that is gumming up the works and causing Parkinson's. Whether AS causes parkinsons and other questions like - do we need some alpha snuclein or how much is too much seem to be yet to be answered. I'm no expert but it seems like phase 2 will happen next year and hopefully phase 3 in 2018. I think studies of the drug Nilotinib are quite promising too and at least 3 studies of this drug are slated to be started in the New Year! Further, it is a drug that has been used for at least 8 years. It increases autophagy which seems to clear alpha snuclein. If the alpha synuclein theory is true I believe we're going to see vast and exciting advances in the next few short years!

At 5 Years, Nilotinib Offers Benefit Over Imatinib in CML | Cancer Network
Everyone has Alpha Synuclein but it is misfolded in Parkinson's patients.

Parkinson's Disease | Podcast: Parkinson's Common Denominator -- A Sticky Protein
zanpar321 is offline   Reply With QuoteReply With Quote